繁體中文
返回
- English
- 繁體中文
- 简体中文
- 深色
- 淺色
牛牛AI助理已提取核心訊息
BeiGene reported total revenues of $929 million in Q2 2024, a 56% increase year-over-year, driven by strong global BRUKINSA sales of $637 million, up 107%. The company reduced GAAP operating loss and achieved positive adjusted operating income for the first time. U.S. BRUKINSA sales grew 114% to $479 million, becoming the BTK inhibitor class leader in new patient starts across all approved indications.Gross margin improved to 85% of product sales, up from 82.7% last year. R&D expenses increased 7.5% to $454 million as the company advanced its innovative pipeline. SG&A expenses rose 12.3% to $444 million to support commercial expansion, but decreased as a percentage of product sales from 71.3% to 48.2% year-over-year.BeiGene ended the quarter with $2.6 billion in cash and investments. The company expects continued revenue and margin expansion in 2024, driven by BRUKINSA's growth. Management highlighted progress in expanding beyond hematology into solid tumors, with over 15 molecules in development including ADCs and targeted therapies for lung, breast and GI cancers.
BeiGene reported total revenues of $929 million in Q2 2024, a 56% increase year-over-year, driven by strong global BRUKINSA sales of $637 million, up 107%. The company reduced GAAP operating loss and achieved positive adjusted operating income for the first time. U.S. BRUKINSA sales grew 114% to $479 million, becoming the BTK inhibitor class leader in new patient starts across all approved indications.Gross margin improved to 85% of product sales, up from 82.7% last year. R&D expenses increased 7.5% to $454 million as the company advanced its innovative pipeline. SG&A expenses rose 12.3% to $444 million to support commercial expansion, but decreased as a percentage of product sales from 71.3% to 48.2% year-over-year.BeiGene ended the quarter with $2.6 billion in cash and investments. The company expects continued revenue and margin expansion in 2024, driven by BRUKINSA's growth. Management highlighted progress in expanding beyond hematology into solid tumors, with over 15 molecules in development including ADCs and targeted therapies for lung, breast and GI cancers.
百濟神州在2024年第二季度報告的營業收入爲92900萬美金，同比增長56%，主要得益於全球BRUKINSA的強勁銷售達到63700萬美金，同比增加107%。公司減少了GAAP運營虧損，並首次實現了正的調整後運營收入。美國BRUKINSA的銷售增長了114%，達到了47900萬美金，成爲BTk抑制劑類別中所有批准適應症中新患者開始治療的領導者。毛利率提高到產品銷售的85%，相比去年82.7%有所上升。研發費用增加了7.5%，達到45400萬美金，因爲公司推進了其創新管道。SG&A費用上升了12.3%，達到44400萬美金，以支持商業擴張，但作爲產品銷售的百分比則從71.3%降至48.2%，同比...展開全部
百濟神州在2024年第二季度報告的營業收入爲92900萬美金，同比增長56%，主要得益於全球BRUKINSA的強勁銷售達到63700萬美金，同比增加107%。公司減少了GAAP運營虧損，並首次實現了正的調整後運營收入。美國BRUKINSA的銷售增長了114%，達到了47900萬美金，成爲BTk抑制劑類別中所有批准適應症中新患者開始治療的領導者。毛利率提高到產品銷售的85%，相比去年82.7%有所上升。研發費用增加了7.5%，達到45400萬美金，因爲公司推進了其創新管道。SG&A費用上升了12.3%，達到44400萬美金，以支持商業擴張，但作爲產品銷售的百分比則從71.3%降至48.2%，同比減少。百濟神州在本季度結束時擁有26億美金的現金和投資。公司預計在2024年將繼續實現營業收入和毛利率的提升，這主要得益於BRUKINSA的增長。管理層強調在擴展到固體腫瘤方面取得了進展，開發了超過15種分子，包括用於肺癌、乳腺癌及胃腸道癌症的ADC和靶向療法。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了